Angela Macia Ortega

Dr. Angela Macia Ortega

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
CTCharles A. Thomas
Charles A. Thomas
LTLeon Tejwani
Leon Tejwani
CTCleber A. Trujillo
Cleber A. Trujillo
PNPriscilla D. Negraes
Priscilla D. Negraes
RHRoberto Herai
Roberto Herai
AMAlysson Muotri
Alysson Muotri

16 July 2010 in Stem Cells
Verified
Journal Article
Open access
PDF file
IGIvan Gutierrez-Aranda
Ivan Gutierrez-Aranda
VRVeronica Ramos-Mejia
Veronica Ramos-Mejia
CBClara Bueno
Clara Bueno
MMMartin Munoz-Lopez
Martin Munoz-Lopez
PRPedro Jose Real
Pedro Jose Real
PMPablo Menendez
Pablo Menendez

9 December 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NCNicole G. Coufal
Nicole G. Coufal
JGJosè Luis Garcia-Perez
Josè Luis Garcia-Perez
GPGrace E. Peng
Grace E. Peng
MMMaria C. N. Marchetto
Maria C. N. Marchetto
AMAlysson R. Muotri
Alysson R. Muotri
FGFred H. Gage
Fred H. Gage
Long interspersed element-1 (L1) retrotransposons compose ∼20% of the mammalian genome, and ongoing L1 retrotransposition events can impact genetic diversity by various mechanisms. Previous studies have demonstrated that endogenous L1 retrotransposition can occur in the germ line and during early embryonic development. In addition, recent data indicate that engineered human L1s can undergo somatic retrotransposition in human neural progenitor cells and that an increase in human-specific L1 DNA content can be detected in the brains of normal controls, as well as in Rett syndrome patients. Here, we demonstrate an increase in the retrotransposition efficiency of engineered human L1s in cells that lack or contain severely reduced levels of ataxia telangiectasia mutated, a serine/threonine kinase involved in DNA damage signaling and neurodegenerative disease. We demonstrate that the increase in L1 retrotransposition in ataxia telangiectasia mutated-deficient cells most likely occurs by conventional target-site primed reverse transcription and generate either longer, or perhaps more, L1 retrotransposition events per cell. Finally, we provide evidence suggesting an increase in human-specific L1 DNA copy number in postmortem brain tissue derived from ataxia telangiectasia patients compared with healthy controls. Together, these data suggest that cellular proteins involved in the DNA damage response may modulate L1 retrotransposition.

11 October 2011 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SWSilke Wissing
Silke Wissing
MMMartin Muñoz-Lopez
Martin Muñoz-Lopez
AOAngela Macia Ortega
Angela Macia Ortega
ZYZhiyuan Yang
Zhiyuan Yang
MMMauricio Montano
Mauricio Montano
WGWarner C. Greene
Warner C. Greene
Long interspersed element-1 (LINE-1 or L1) retrotransposons account for nearly 17% of human genomic DNA and represent a major evolutionary force that has reshaped the structure and function of the human genome. However, questions remain concerning both the frequency and the developmental timing of L1 retrotransposition in vivo and whether the mobility of these retroelements commonly results in insertional and post-insertional mechanisms of genomic injury. Cells exhibiting high rates of L1 retrotransposition might be especially at risk for such injury. We assessed L1 mRNA expression and L1 retrotransposition in two biologically relevant cell types, human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), as well as in control parental human dermal fibroblasts (HDFs). Full-length L1 mRNA and the L1 open reading frame 1-encoded protein (ORF1p) were readily detected in hESCs and iPSCs, but not in HDFs. Sequencing analysis proved the expression of human-specific L1 element mRNAs in iPSCs. Bisulfite sequencing revealed that the increased L1 expression observed in iPSCs correlates with an overall decrease in CpG methylation in the L1 promoter region. Finally, retrotransposition of an engineered human L1 element was ∼10-fold more efficient in iPSCs than in parental HDFs. These findings indicate that somatic cell reprogramming is associated with marked increases in L1 expression and perhaps increases in endogenous L1 retrotransposition, which could potentially impact the genomic integrity of the resultant iPSCs.

13 December 2016 in Genome Research
Verified
Journal Article
Open access
PDF file
AOAngela Macia Ortega
Angela Macia Ortega
TWThomas J. Widmann
Thomas J. Widmann
SHSara R Heras
Sara R Heras
VAVeronica Ayllon
Veronica Ayllon
LSLaura Sanchez
Laura Sanchez
JGJose L. Garcia-Perez
Jose L. Garcia-Perez
Half the human genome is made of transposable elements (TEs), whose ongoing activity continues to impact our genome. LINE-1 (or L1) is an autonomous non-LTR retrotransposon in the human genome, comprising 17% of its genomic mass and containing an average of 80–100 active L1s per average genome that provide a source of inter-individual variation. New LINE-1 insertions are thought to accumulate mostly during human embryogenesis. Surprisingly, the activity of L1s can further impact the somatic human brain genome. However, it is currently unknown whether L1 can retrotranspose in other somatic healthy tissues or if L1 mobilization is restricted to neuronal precursor cells (NPCs) in the human brain. Here, we took advantage of an engineered L1 retrotransposition assay to analyze L1 mobilization rates in human mesenchymal (MSCs) and hematopoietic (HSCs) somatic stem cells. Notably, we have observed that L1 expression and engineered retrotransposition is much lower in both MSCs and HSCs when compared to NPCs. Remarkably, we have further demonstrated for the first time that engineered L1s can retrotranspose efficiently in mature nondividing neuronal cells. Thus, these findings suggest that the degree of somatic mosaicism and the impact of L1 retrotransposition in the human brain is likely much higher than previously thought.

1 August 2019 in Molecular Cell
Verified
Journal Article
Closed access
FSFrancisco J. Sanchez-Luque
Francisco J. Sanchez-Luque
MKMarie-Jeanne H.C. Kempen
Marie-Jeanne H.C. Kempen
PGPatricia Gerdes
Patricia Gerdes
DVDulce B. Vargas-Landin
Dulce B. Vargas-Landin
SRSandra R. Richardson
Sandra R. Richardson
GFGeoffrey Faulkner
Geoffrey Faulkner